Pentixapharm Holding AG (ETR:PTP) | WebDisclosure

Basculer en Français

11080	Companies
243107	Keywords
171250	Articles
130872	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

PRESS RELEASE

published on 10/06/2025 at 11:00, 11 months 18 days ago

Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
Pentixapharm presents new clinical findings on expanding CXCR4 radiopharmaceutical platform at EANM 2025, demonstrating potential in diagnosis and therapeutics in Primary Aldosteronism and bladder cancer

Pentixapharm CXCR4 Radiopharmaceutical EANM 2025 Clinical Findings
BRIEF

published on 09/26/2025 at 08:05, 11 months 28 days ago

Pentixapharm Advances PentixaTher in AML Trial

Clinical Trial Radiopharmaceuticals Acute Myeloid Leukemia PentixaTher CXCR4-targeting
BRIEF

published on 09/26/2025 at 08:05, 11 months 28 days ago

Pentixapharm fait progresser PentixaTher dans l'essai sur la LAM

Essai Clinique Produits Radiopharmaceutiques Ciblage CXCR4 Leucémie Myéloïde Aiguë PentixaTher
PRESS RELEASE

published on 09/26/2025 at 08:00, 11 months 28 days ago

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial
Pentixapharm advances PentixaTher to fourth dose level in AML trial, reinforcing safety profile and potential clinical efficacy for CXCR4-targeted radiotherapeutic in high unmet need indication

Pentixapharm CXCR4 Acute Myeloid Leukemia Radiotherapeutic PentixaTher
BRIEF

published on 05/27/2025 at 09:48, 1 year 3 months ago

Pentixapharm Unveils New Clinical Development Strategy

Oncology Pentixapharm CXCR4 Trials Theranostic Strategy Hematologic Malignancies
BRIEF

published on 05/27/2025 at 09:48, 1 year 3 months ago

Pentixapharm dévoile une nouvelle stratégie de développement clinique

Oncologie Pentixapharm Essais CXCR4 Stratégie Théranostique Hémopathies Malignes
PRESS RELEASE

published on 05/27/2025 at 09:43, 1 year 3 months ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Pentixapharm outlines new clinical development strategy focusing on CXCR4 therapeutic and diagnostic oncology programs, discontinuing PTF301 trial in MZL, preparing new trials in hematologic malignancies and Bladder Cancer

Pentixapharm CXCR4 Oncology Programs Clinical Development Strategy Theranostic Precision
BRIEF

published on 04/25/2025 at 15:44, 1 year 4 months ago

Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025

Cancer Therapy Pentixapharm GT-008 Antibody Glycan-Dependent CD24 Targeting
BRIEF

published on 04/25/2025 at 15:44, 1 year 4 months ago

Pentixapharm présentera son anticorps innovant GT-008 à l'AACR 2025

Thérapie Contre Le Cancer Pentixapharm Anticorps GT-008 Glycane-dépendant Ciblage CD24
PRESS RELEASE

published on 04/25/2025 at 15:39, 1 year 4 months ago

Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
Pentixapharm to present novel CD24 antibody GT-008 for solid tumors at AACR 2025, showcasing glycan-dependent mechanism for targeted therapy

Solid Tumors Pentixapharm AACR 2025 GT-008 CD24 Antibody

Accesswire

Published on 09/25/2026 at 00:30, 1 hour 35 minutes ago

Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Published on 09/25/2026 at 00:15, 1 hour 50 minutes ago

CoTec Holdings Corp. Announces Extension of Private Placement of Unsecured Convertible Debentures
Published on 09/24/2026 at 22:01, 4 hours 4 minutes ago

Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 17:45, 8 hours 20 minutes ago

Jo-Jo Announces Resignation of Director
Published on 09/24/2026 at 14:55, 11 hours 10 minutes ago

Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements

View all ACCESSWIRE

EQS Group

Published on 09/24/2026 at 20:29, 5 hours 36 minutes ago

EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 7 hours 5 minutes ago

HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 7 hours 24 minutes ago

EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:15, 7 hours 50 minutes ago

Epanko Value Engineering Identifies 20% Production Increase
Published on 09/24/2026 at 18:05, 7 hours 59 minutes ago

DCK Tools Showcases Expanded Outdoor Power Equipment Lineup at Salonvert 2026

Les Echos

Published on 09/24/2026 at 18:31, 7 hours 33 minutes ago

LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:10, 7 hours 55 minutes ago

Financial statements - 30 june 2026
Published on 09/24/2026 at 18:00, 8 hours 5 minutes ago

GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 8 hours 5 minutes ago

GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 09/24/2026 at 18:00, 8 hours 5 minutes ago

i2S : Résultats 1er semestre 2026

View all LES ECHOS COMFI WIRE